All Photos(1)

P0080

Sigma-Aldrich

Pranlukast hemihydrate

≥98% (HPLC), white, solid

Synonym(s):
8-[4(4-phenylbutoxy)benzoyl]amino-2-(5-tetrazolyl)-4-oxo-4H-1-benzopyran
Empirical Formula (Hill Notation):
C27H23N5O4 · 0.5 H2O
CAS Number:
Molecular Weight:
490.51
MDL number:
PubChem Substance ID:
NACRES:
NA.77

Quality Level

assay

≥98% (HPLC)

form

solid

color

white

solubility

DMSO: ≥10 mg/mL
H2O: insoluble

storage temp.

−20°C

SMILES string

O.O=C(Nc1cccc2C(=O)C=C(Oc12)c3nnn[nH]3)c4ccc(OCCCCc5ccccc5)cc4.O=C(Nc6cccc7C(=O)C=C(Oc67)c8nnn[nH]8)c9ccc(OCCCCc%10ccccc%10)cc9

InChI

1S/2C27H23N5O4.H2O/c2*33-23-17-24(26-29-31-32-30-26)36-25-21(23)10-6-11-22(25)28-27(34)19-12-14-20(15-13-19)35-16-5-4-9-18-7-2-1-3-8-18;/h2*1-3,6-8,10-15,17H,4-5,9,16H2,(H,28,34)(H,29,30,31,32);1H2

InChI key

MSXTUBJFNBZPGC-UHFFFAOYSA-N

Packaging

5, 25 mg in glass bottle

Biochem/physiol Actions

Pranlukast is a subtype specific CysLT1 receptor antagonist. Leukotrienes are involved in the inflammation response and are divided into two main classes; leukotriene B4 and cysteinyl-substituted leukotrienes.

Features and Benefits

This compound is featured on the Leukotriene Receptors page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Chronic 4 - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

Target Organs

Respiratory system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificate of Analysis

Certificate of Origin

Inés Velázquez-Quesada et al.
Drug design, development and therapy, 14, 1799-1811 (2020-06-05)
Cancer stem cells (CSCs) drive the initiation, maintenance, and therapy response of breast tumors. CD49f is expressed in breast CSCs and functions in the maintenance of stemness. Thus, blockade of CD49f is a potential therapeutic approach for targeting breast CSCs.
Eun-Sol Ha et al.
Drug design, development and therapy, 9, 3257-3266 (2015-07-08)
The present study was carried out to develop an oral formulation of pranlukast hemihydrate with improved dissolution and oral bioavailability using a surface-modified microparticle. Based on solubility measurements, surface-modified pranlukast hemihydrate microparticles were manufactured using the spray-drying method with hydroxypropylmethyl

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service